Sarepta Stock Soars 9.92% on FDA's Elevidys Resumption

On July 30, 2025, Sarepta's stock surged by 9.92% in pre-market trading, marking a significant rise that caught the attention of investors and analysts alike.

Sarepta Therapeutics' stock experienced a notable jump after the company resumed shipments of its medicine Elevidys, which had been paused by the FDA due to safety concerns. This decision by the FDA to lift the hold on Elevidys shipments was a pivotal moment for the company, as it addressed two major concerns that had been weighing on Sarepta's stock.

JPMorgan upgraded Sarepta's stock from Underweight to Neutral, setting a price target of $24 following the FDA's recommendation to resume Elevidys shipments. This upgrade reflects the positive sentiment surrounding the regulatory developments and their potential impact on Sarepta's future performance.

The FDA's decision to resume Elevidys shipments has enabled Sarepta's stock to surge, highlighting the significant impact of regulatory developments on investor confidence. The lifting of the hold on Elevidys has erased two of the biggest apprehensions hovering over Sarepta, leading to a nearly 48% increase in its stock price.